Roohi Mariam Peter
Junior Reporter at Labiotech
Journalist @Labiotech_eu | MA International Journalism @cardiffjomec | she/her
Articles
-
3 days ago |
labiotech.eu | Roohi Mariam Peter
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Once hailed as the solution to delivering gene therapies, adeno-associated virus (AAV) vectors have seen their star dim in recent years.
-
1 week ago |
labiotech.eu | Roohi Mariam Peter
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*PhoneThis field is for validation purposes and should be left unchanged. In the vast field of immunotherapy, toll-like receptor agonists (TLR) emerged as powerful catalysts to boost the immune system.
-
1 week ago |
labiotech.eu | Roohi Mariam Peter
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Biotech deals are known to . In the month of April 2025, a number of pharma giants took part in mergers and acquisitions (M&As) as well as licensing deals. Some of these included Lilly, Merck, and Boehringer Ingelheim.
-
2 weeks ago |
labiotech.eu | Roohi Mariam Peter
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. For decades, non-small cell lung cancer (NSCLC) stood as one of the formidable challenges in oncology, often diagnosed late and treated with limited options. But now, it looks like the therapeutic field is changing.
-
2 weeks ago |
labiotech.eu | Roohi Mariam Peter
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*EmailThis field is for validation purposes and should be left unchanged. As the world flocks towards medical research and innovation, the U.S. is hitting the brakes. Sweeping cuts across federal research programs are threatening to stall scientific progress and could dim the country’s edge.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 126
- Tweets
- 65
- DMs Open
- Yes
RT @OojalKour: 📢I’m officially looking for a job! I’m a multimedia journalist who's covered LGBTQIA+ issues🏳️🌈, trade unionism, social jus…
RT @Labiotech_eu: As biotech startups navigate the growing biotech sector in Wales, here are five companies that are making waves in 2023.…
RT @Labiotech_eu: The European Commission has approved the first gene therapy for the treatment of hemophilia B developed by biotech compan…